Ritter Daniher Financial Advisory’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Ritter Daniher Financial Advisory’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20	Closed	-$768	–	316
2024 Q4	$768	Hold	20	–	–	﹤0.01%	299
2024 Q3	$889	Hold	20	–	–	﹤0.01%	299
2024 Q2	$825	Hold	20	–	–	﹤0.01%	295
2024 Q1	$900	Hold	20	–	–	﹤0.01%	288
2023 Q4	$914	Hold	20	–	–	﹤0.01%	328
2023 Q3	$804	Hold	20	–	–	﹤0.01%	333
2023 Q2	$958	Sell	20 -19	-49%	-$950	﹤0.01%	303
2023 Q1	$1.9K	Hold	39	–	–	﹤0.01%	260
2022 Q4	$1.95K	Buy	+39	New	+$2.01K	﹤0.01%	244

Other funds holding GNOM

OCM

One Capital Management Westlake Village, California $3.6B AUM 16.02% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $83.9B AUM 60.43% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return

OAM

Oppenheimer Asset Management New York $9.63B AUM 30.32% 1-Year Est. Return

Ritter Daniher Financial Advisory's GNOM Position: Q1 2025 in Review

Ritter Daniher Financial Advisory sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q1 2025, closing a stake of 20 shares — an estimated $768 sold.

Ritter Daniher Financial Advisory first reported a position in GNOM in Q4 2022 and held it in 9 quarters. The position peaked at $1.95K in Q4 2022. 60 funds tracked by Wall St. Rank hold GNOM as of Q1 2025.

Ritter Daniher Financial Advisory reported no remaining Global X Genomics & Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
Ritter Daniher Financial Advisory sold 20 Global X Genomics & Biotechnology ETF shares in Q1 2025, an estimated $768.
Ritter Daniher Financial Advisory first reported a position in Global X Genomics & Biotechnology ETF in Q4 2022 and held it in 9 quarters.
Ritter Daniher Financial Advisory's Global X Genomics & Biotechnology ETF position peaked at $1.95K in Q4 2022.
60 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2025.

Based on Ritter Daniher Financial Advisory's 13F filing for Q1 2025, filed 9 May 2025.